CIRS Evidence Grade vs Mainstream Mold Medicine

False balance treats a clinic protocol as equal to WHO guidelines. False dismissal denies all damp-building health effects because CIRS is contested. Neither is science.

This article is informational and editorial only. It is not medical advice, diagnosis, or a treatment plan. Numbers and literature ranges cited here are not personal prescriptions. Consult a qualified clinician before changing medications, supplements, diet, equipment, or management of a diagnosed condition. Seek urgent care for emergencies.

What is established versus contested?

Established: damp/mold indicators and respiratory symptoms or asthma exacerbation; increased odds of asthma development in meta-analyses; hypersensitivity pneumonitis in susceptibles; infection risk if immunocompromised; food mycotoxin organ toxicity at dietary doses.

Contested or not established as marketed: residential air mycotoxins causing multi-system toxic mold syndrome at typical doses; CIRS as consensus diagnosis; cholestyramine as standard biotoxin cure; ERMI diagnosing individual illness; urine mycotoxins diagnosing indoor mold disease.

How does mainstream allergy and pulmonology approach damp-building illness?

Mechanisms center on IgE sensitization, innate irritation from fragments and microbial products, and hypersensitivity pneumonitis pathways. Workup uses history, spirometry, targeted allergy testing, and further imaging or PFTs when HP is suspected.

Treatment prioritizes environmental control and guideline asthma or allergy medications—not binder cascades first.

What evidence-quality problems appear in contested protocol literature?

Small clinics, limited blinding, selection bias, nonspecific overlapping symptoms and labs, inadequate control for diet (urine toxins), psychosocial stress, and comorbid asthma or sleep disorders. Commercial testing ecosystems can create conflicts of interest.

ACMT-aligned messaging emphasizes lack of toxicological evidence that inhaled indoor mycotoxins cause systemic toxicity syndromes as commonly claimed.

What hierarchy should patients and clinicians use?

Moisture fix and leaving water-damaged environments when needed (higher confidence) → symptom-guided mainstream care → experimental protocols only with clear informed consent about evidence limits. Never imply ACMT, CDC, or WHO endorse Shoemaker protocol as consensus standard.

Sources: ACMT mold exposure guidance; UCLA Health on CIRS diagnosis status; CDC MMWR urine mycotoxin tests.

Readers should dual-source primary literature, translate slogans into exposure units and effect sizes, and rank interventions by expected value under uncertainty. Cheap reversible steps often outrank extreme protocols. Opportunity cost is real: hours spent on unvalidated tests are hours not spent on sleep, training, protein adequacy, and primary care. Sex, life stage, comorbidities, medications, and geography change interpretation. Prefer falsifiable claims with named endpoints over multi-disease cure lists. Update beliefs when stronger trials appear rather than freezing identity around a single paper or influencer narrative. Measured curiosity beats both panic and complacency. Further reading should prioritize primary sources and consensus documents over secondary social summaries. When evidence is mixed, state both the signal and the limits in the same paragraph. When evidence is strong, still avoid overclaiming universality across populations.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.

Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims.